Milrinone controlled-release formulation
AssigneeCardiora Pty Ltd.
InventorsDavid Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
Life of this patent
Estimating the term…
Abstract
The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 μg/kg body weight/minute and 20 μg/kg body weight/minute.
Claims24
A method for treating a subject exhibiting symptoms of heart failure or pulmonary hypertension, said method comprising administering to the subject an oral controlled-release formulation comprising:
- (i) a core comprising:
- (a) milrinone, or a pharmaceutically acceptable salt thereof;
- (b) hydroxyproplmethylcellulose having a viscosity of 80,000 to 120,000 cps;
- (c) hydroxypropylmethylcellulose having a viscosity of about 50 cps;
- and
- (d) at least one pharmaceutically acceptable excipient;
- (ii) a sustained-release coating;
- and
- (iii) an enteric coating;
- wherein the hydroxypropylmethylcellulose (80,000 to 120,000 cps) and the hydroxypropylmethylcellulose (about 50 cps) are in a ratio of about 1.5:1 to 1:1.5, and the ratio of milrinone, or a pharmaceutically acceptable salt thereof, to total hydroxypropylmethylcellulose is about 1:3 to 1:5, and
- wherein the formulation exhibits zero order release of about 100% of milrinone, or a pharmaceutically acceptable salt thereof, over about 12 hours at pH 6.8.
Dependencies are inferred from the claim text.